MC
DMAAR

Meteora Capital’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Meteora Capital’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-182,581
Closed -$11K – 471
2026
Q1 		$11K Buy
182,581
+180,581
+9,029% +$19.1K ﹤0.01% 311
2025
Q4 		$375 Buy
+2,000
New +$388 ﹤0.01% 359

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Meteora Capital's DMAAR Position: Q2 2026 in Review

Meteora Capital sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q2 2026, closing a stake of 182,581 shares — an estimated $11K sold.

Meteora Capital first reported a position in DMAAR in Q4 2025 and held it in 2 quarters. The position peaked at $11K in Q1 2026. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • Meteora Capital reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q2 2026 after selling out during the quarter.
  • Meteora Capital sold 182,581 Drugs Made In America Acquisition Corp Rights shares in Q2 2026, an estimated $11K.
  • Meteora Capital first reported a position in Drugs Made In America Acquisition Corp Rights in Q4 2025 and held it in 2 quarters.
  • Meteora Capital's Drugs Made In America Acquisition Corp Rights position peaked at $11K in Q1 2026.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Meteora Capital's 13F filing for Q2 2026, filed 14 Aug 2026.